Market Trends Toward New Normal in Zillow Group, YRC Worldwide, The Home Depot, UROGEN PHARMA, ZIOPHARM Oncology, and Cinedigm — Emerging Consolidated Expectations, Analyst Ratings

Loading...
Loading...

NEW YORK, Dec. 03, 2018 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Zillow Group, Inc. Z, YRC Worldwide, Inc. YRCW, The Home Depot, Inc. HD, UROGEN PHARMA URGN, ZIOPHARM Oncology Inc ZIOP, and Cinedigm Corp CIDM, including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.

Complimentary Access: Research Reports

Full copies of recently published reports are available to readers at the links below.

Z DOWNLOAD: http://Fundamental-Markets.com/register/?so=Z
YRCW DOWNLOAD: http://Fundamental-Markets.com/register/?so=YRCW
HD DOWNLOAD: http://Fundamental-Markets.com/register/?so=HD
URGN DOWNLOAD: http://Fundamental-Markets.com/register/?so=URGN
ZIOP DOWNLOAD: http://Fundamental-Markets.com/register/?so=ZIOP
CIDM DOWNLOAD: http://Fundamental-Markets.com/register/?so=CIDM

(You may have to copy and paste the link into your browser and hit the [ENTER] key)

The new research reports from Fundamental Markets, available for free download at the links above, examine Zillow Group, Inc. Z, YRC Worldwide, Inc. YRCW, The Home Depot, Inc. HD, UROGEN PHARMA URGN, ZIOPHARM Oncology Inc ZIOP, and Cinedigm Corp CIDM on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.

-----------------------------------------

Important Notice: the following excerpts are not designed to be standalone summaries and as such, important information may be missing from these samples. Please download the entire research report, free of charge, to ensure you are reading all relevant material information. All information in this release was accessed November 28th, 2018. Percentage calculations are performed after rounding. All amounts in millions (MM), except per share amounts.

-----------------------------------------

Loading...
Loading...

Zillow Group, Inc. (Z) REPORT OVERVIEW

Zillow Group's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Zillow Group reported revenue of $343.09MM vs $281.84MM (up 21.73%) and analysts estimated basic earnings per share -$0.00 vs $0.05. For the twelve months ended December 31st, 2017 vs December 31st, 2016, Zillow Group reported revenue of $1,076.79MM vs $846.59MM (up 27.19%) and analysts estimated basic earnings per share -$0.51 vs -$1.22. Analysts expect earnings to be released on February 14th, 2019. The report will be for the fiscal period ending December 31st, 2018.

To read the full Zillow Group, Inc. (Z) report, download it here: http://Fundamental-Markets.com/register/?so=Z

-----------------------------------------

YRC Worldwide, Inc. (YRCW) REPORT OVERVIEW

YRC Worldwide's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, YRC Worldwide reported revenue of $1,303.60MM vs $1,251.20MM (up 4.19%) and analysts estimated basic earnings per share $0.09 vs $0.09 (unchanged). For the twelve months ended December 31st, 2017 vs December 31st, 2016, YRC Worldwide reported revenue of $4,891.00MM vs $4,697.50MM (up 4.12%) and analysts estimated basic earnings per share -$0.33 vs $0.66. Analysts expect earnings to be released on February 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. Reported EPS for the same quarter last year was $0.04. The estimated EPS forecast for the next fiscal year is $1.13 and is expected to report on February 7th, 2019.

To read the full YRC Worldwide, Inc. (YRCW) report, download it here: http://Fundamental-Markets.com/register/?so=YRCW

-----------------------------------------

The Home Depot, Inc. (HD) REPORT OVERVIEW

The Home Depot's Recent Financial Performance

For the three months ended October 31st, 2018 vs October 31st, 2017, The Home Depot reported revenue of $26,302.00MM vs $25,026.00MM (up 5.10%) and analysts estimated basic earnings per share $2.53 vs $1.85 (up 36.76%). For the twelve months ended January 31st, 2018 vs January 31st, 2017, The Home Depot reported revenue of $100,904.00MM vs $94,595.00MM (up 6.67%) and analysts estimated basic earnings per share $7.33 vs $6.47 (up 13.29%). Analysts expect earnings to be released on February 19th, 2019. The report will be for the fiscal period ending January 31st, 2019. Based on 15 analysts' forecasts, the consensus EPS forecast for the quarter is $2.27. Reported EPS for the same quarter last year was $1.69. The estimated EPS forecast for the next fiscal year is $10.23 and is expected to report on February 19th, 2019.

To read the full The Home Depot, Inc. (HD) report, download it here: http://Fundamental-Markets.com/register/?so=HD

-----------------------------------------

UROGEN PHARMA (URGN) REPORT OVERVIEW

UROGEN PHARMA's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, UROGEN PHARMA reported revenue of $0.28MM vs $7.81MM (down 96.38%) and basic earnings per share -$1.28 vs -$0.02. For the twelve months ended December 31st, 2017 vs December 31st, 2016, UROGEN PHARMA reported revenue of $8.16MM vs $17.53MM (down 53.46%) and analysts estimated basic earnings per share -$2.14 vs -$1.91. Analysts expect earnings to be released on March 21st, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.74. The estimated EPS forecast for the next fiscal year is -$5.27 and is expected to report on March 21st, 2019.

To read the full UROGEN PHARMA (URGN) report, download it here: http://Fundamental-Markets.com/register/?so=URGN

-----------------------------------------

ZIOPHARM Oncology Inc (ZIOP) REPORT OVERVIEW

ZIOPHARM Oncology's Recent Financial Performance

For the twelve months ended December 31st, 2017 vs December 31st, 2016, ZIOPHARM Oncology reported revenue of $6.39MM vs $6.86MM (down 6.88%) and analysts estimated basic earnings per share -$0.53 vs -$1.32. Analysts expect earnings to be released on March 7th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.13. The estimated EPS forecast for the next fiscal year is -$0.32 and is expected to report on March 7th, 2019.

To read the full ZIOPHARM Oncology Inc (ZIOP) report, download it here: http://Fundamental-Markets.com/register/?so=ZIOP

-----------------------------------------

Cinedigm Corp (CIDM) REPORT OVERVIEW

Cinedigm's Recent Financial Performance

For the three months ended September 30th, 2018 vs September 30th, 2017, Cinedigm reported revenue of $13.74MM vs $16.28MM (down 15.57%) and analysts estimated basic earnings per share -$0.09 vs -$0.60. For the twelve months ended March 31st, 2018 vs March 31st, 2017, Cinedigm reported revenue of $67.68MM vs $90.39MM (down 25.12%) and analysts estimated basic earnings per share -$0.81 vs -$1.92. Analysts expect earnings to be released on February 13th, 2019. The report will be for the fiscal period ending December 31st, 2018. The reported EPS for the same quarter last year was -$0.20. The estimated EPS forecast for the next fiscal year is -$0.52 and is expected to report on June 24th, 2019.

To read the full Cinedigm Corp (CIDM) report, download it here: http://Fundamental-Markets.com/register/?so=CIDM

-----------------------------------------

ABOUT Fundamental Markets

Fundamental Markets serves thousands of members and have provided research through some of the world's leading brokerages for over a decade–and continue to be one of the best information sources for investors and investment professionals worldwide. Fundamental Markets' roster boasts decades of financial experience and includes top financial writers, FINRA® BrokerCheck® certified professionals with current and valid CRD® number designations, as well as Chartered Financial Analyst® (CFA®) designation holders, to ensure up to date factual information for active readers on the topics they care about.

REGISTERED MEMBER STATUS

Fundamental Markets' oversight and audit staff are registered analysts, brokers, and/or financial advisers ("Registered Members") working within Equity Research, Media, and Compliance departments. Fundamental Markets' roster includes qualified CFA® charterholders, licensed securities attorneys, and registered FINRA® members holding duly issued CRD® numbers. Current licensed status of several Registered Members at Fundamental Markets have been independently verified by an outside audit firm, including policy and audit records duly executed by Registered Members. Complaints, concerns, questions, or inquiries regarding this release should be directed to Fundamental Markets' Compliance department by Phone, at +1 667-401-0010, or by E-mail at compliance@Fundamental-Markets.com.

LEGAL NOTICES

Information contained herein is not an offer or solicitation to buy, hold, or sell any security. Fundamental Markets, Fundamental Markets members, and/or Fundamental Markets affiliates are not responsible for any gains or losses that result from the opinions expressed. Fundamental Markets makes no representations as to the completeness, accuracy, or timeliness of the material provided and all materials are subject to change without notice. Fundamental Markets has not been compensated for the publication of this press release by any of the above mentioned companies. Fundamental Markets is not a financial advisory firm, investment adviser, or broker-dealer, and does not undertake any activities that would require such registration. For our full disclaimer, disclosure, and terms of service please visit our website.

Media Contact:
Andrew Duffie, Media Department
Office: +1 667-401-0010
E-mail: media@Fundamental-Markets.com

© 2018 Fundamental Markets. All Rights Reserved. For republishing permissions, please contact a partner network manager at partnership@Fundamental-Markets.com.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

FINRA®, BrokerCheck®, and CRD® are registered trademarks owned by Financial Industry Regulatory Authority, Inc.

Loading...
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst RatingsPress Releases
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...